Dataset from A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX

The study objective of Period 1 of this study is to compare the safety and efficacy (signs
and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone
versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis
(RA) with an inadequate response to MTX.

The study objective of Period 2 is to evaluate the long term safety, tolerability, and
efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.